259 related articles for article (PubMed ID: 34201065)
1. Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.
Puro V; Castilletti C; Agrati C; Goletti D; Leone S; Agresta A; Cimini E; Tartaglia E; Casetti R; Colavita F; Meschi S; Matusali G; Lapa D; Najafi Fard S; Aiello A; Farrone C; Gallì P; Capobianchi MR; Ippolito G; On Behalf Of The Inmi Covid-Vaccine Study Group
Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34201065
[TBL] [Abstract][Full Text] [Related]
2. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E;
Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
4. Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
Cavalcanti E; Isgrò MA; Rea D; Di Capua L; Trillò G; Russo L; Botti G; Miscio L; Buonaguro FM; Bianchi AAM
Infect Agent Cancer; 2021 May; 16(1):32. PubMed ID: 33980271
[TBL] [Abstract][Full Text] [Related]
5. Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine.
Coppeta L; Ferrari C; Somma G; Mazza A; D'Ancona U; Marcuccilli F; Grelli S; Aurilio MT; Pietroiusti A; Magrini A; Rizza S
Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214600
[TBL] [Abstract][Full Text] [Related]
6. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.
Goupil R; Benlarbi M; Beaubien-Souligny W; Nadeau-Fredette AC; Chatterjee D; Goyette G; Gunaratnam L; Lamarche C; Tom A; Finzi A; Suri RS;
CMAJ; 2021 May; 193(22):E793-E800. PubMed ID: 33980499
[TBL] [Abstract][Full Text] [Related]
7. Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2.
Salvaggio M; Fusina F; Albani F; Salvaggio M; Beschi R; Ferrari E; Costa A; Agnoletti L; Facchi E; Natalini G
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575315
[TBL] [Abstract][Full Text] [Related]
8. Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers.
Vassilaki N; Gargalionis AN; Bletsa A; Papamichalopoulos N; Kontou E; Gkika M; Patas K; Theodoridis D; Manolis I; Ioannidis A; Milona RS; Tsirogianni A; Angelakis E; Chatzipanagiotou S
Microorganisms; 2021 Aug; 9(8):. PubMed ID: 34442806
[TBL] [Abstract][Full Text] [Related]
9. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study.
Vollenberg R; Tepasse PR; Lorentzen E; Nowacki TM
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629116
[TBL] [Abstract][Full Text] [Related]
10. Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine.
Agrati C; Castilletti C; Goletti D; Meschi S; Sacchi A; Matusali G; Bordoni V; Petrone L; Lapa D; Notari S; Vanini V; Colavita F; Aiello A; Agresta A; Farroni C; Grassi G; Leone S; Vaia F; Capobianchi MR; Ippolito G; Puro V; On Behalf Of The Inmi Covid-Vaccine Study Group
Microorganisms; 2021 Jun; 9(6):. PubMed ID: 34208751
[TBL] [Abstract][Full Text] [Related]
11. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
12. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
[TBL] [Abstract][Full Text] [Related]
13. Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers.
Salvagno GL; Henry BM; di Piazza G; Pighi L; de Nitto S; Bragantini D; Gianfilippi GL; Lippi G
J Med Biochem; 2021 Sep; 40(4):327-334. PubMed ID: 34616222
[TBL] [Abstract][Full Text] [Related]
14. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingström J; Gordon M; Åberg M; Thålin C
Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35334989
[TBL] [Abstract][Full Text] [Related]
15. Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents-The Data from the Study among Healthcare Workers in an Infectious Diseases Center.
Skrzat-Klapaczyńska A; Kowalska JD; Paciorek M; Puła J; Bieńkowski C; Krogulec D; Stengiel J; Pawełczyk A; Perlejewski K; Osuch S; Radkowski M; Horban A
Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560567
[TBL] [Abstract][Full Text] [Related]
16. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis.
Espi M; Charmetant X; Barba T; Koppe L; Pelletier C; Kalbacher E; Chalencon E; Mathias V; Ovize A; Cart-Tanneur E; Bouz C; Pellegrina L; Morelon E; Fouque D; Juillard L; Thaunat O
Kidney Int; 2021 Oct; 100(4):928-936. PubMed ID: 34284044
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan.
Sakamoto A; Yoshimura M; Itoh R; Ozuru R; Ishii K; Sechi Y; Nabeshima S; Hiromatsu K
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746438
[TBL] [Abstract][Full Text] [Related]
18. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.
Salvagno GL; Henry BM; di Piazza G; Pighi L; De Nitto S; Bragantini D; Gianfilippi GL; Lippi G
Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34064509
[TBL] [Abstract][Full Text] [Related]
19. Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers.
Greco M; Cucci F; Portulano P; Lazzari RA; Caldararo C; Sicuro F; Catanese C; Lobreglio G
J Clin Med Res; 2021 Dec; 13(12):549-555. PubMed ID: 35059073
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine.
Lo Sasso B; Giglio RV; Vidali M; Scazzone C; Bivona G; Gambino CM; Ciaccio AM; Agnello L; Ciaccio M
Diagnostics (Basel); 2021 Jun; 11(7):. PubMed ID: 34206567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
